Close Search X
Smarter Cancer Care
Genomic Health brings the promise of precision medicine
to life with Oncotype IQ, a full suite of genomic tests.

The New Oncotype DX Breast Recurrence Score Report

On 10 December 2018, Genomic Health will begin delivering a newly designed Breast Recurrence Score test report for your HR+, HER2-, early-stage, invasive breast cancer patients.
What Is the Test
The Oncotype DX test reveals the underlying tumour biology to help guide treatment decisions.
Learn More
Getting Tested
The Oncotype DX test should be used when the benefit of chemotherapy for a patient is uncertain.
Learn More
Oncotype DX Patient Report
The Oncotype DX patient report for invasive breast cancer provides clear information for determining chemotherapy benefit and recurrence risk
Learn About the Report
Resources

Visit these pages for further information on the Oncotype DX test and FAQs.
Learn More

Contact Us

 Get in Touch
Copyright © 2004- Genomic Health, Inc., an Exact Sciences corporation. All Rights Reserved.
In the US and certain other jurisdictions, Genomic Health, Oncotype DX, Oncotype IQ, Recurrence Score, Oncotype DX Breast Recurrence Score, Oncotype DX Colon Recurrence Score, Oncotype DX Genomic Prostate Score, and Oncotype DX AR-V7 Nucleus Detect are registered trademarks, and "Making cancer care smarter" and GPS are pending registered trademarks, of Genomic Health, Inc., an Exact Sciences corporation.
Making cancer care smarter.™
X

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.